Pulsenmore has recently announced its selection to participate in the "Israeli Medical AI Regulatory Sandbox" program, a joint initiative by the Israel Innovation Authority and the Ministry of Health. As part of this project, the company will receive approximately $1 million in funding support.

The program aims to foster the development and clinical application of medical AI technologies by establishing a special regulatory framework, creating a clear and efficient pathway for integrating these technologies into both the Israeli and global healthcare systems.

Pulsenmore's home ultrasound platform enables pregnant women, under a doctor's prescription, to perform ultrasound scans at home using the company's device connected to a smartphone. The scan results are then transmitted to a physician for interpretation and clinical decision-making. This technology has already been adopted by institutions including Israel's largest health maintenance organization. To date, the Pulsenmore platform has completed over 250,000 home ultrasound scans, creating the world's largest real-world dataset for prenatal home ultrasound.

Leveraging this program, Pulsenmore will develop and clinically validate an AI application designed to automatically identify key ultrasound parameters and present results to doctors, thereby optimizing clinical workflows. This has the potential to help physicians deliver results faster, serve more patients, and alleviate the global shortage of specialized healthcare professionals. The company will collaborate with local Israeli medical institutions to advance the development and clinical validation of the AI application.

The company's founder and CEO stated that this program marks the next phase in the development of the company's platform, with the goal of providing doctors with more efficient tools to serve more patients while maintaining the quality of care.